Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.56 |
| ▸ | NQO1 | P15559 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15843118 | 0.87 | PTGS2 (0.59) | PTGS2NQO1CA12CA1CA9 | |
| SCHEMBL14329527 | 0.82 | PTGS2 (0.57) | PTGS2NQO1CA12CA1CA9 | |
| SCHEMBL14802636 | 0.82 | PTGS2 (0.57) | PTGS2NQO1CA12CA1CA9 | |
| SCHEMBL15864643 | 0.81 | NQO1 (0.56) | PTGS2NQO1CA12CA1CA9 | |
| SCHEMBL14329522 | 0.80 | PTGS2 (0.55) | PTGS2NQO1CA12CA1CA9 | |
| SCHEMBL14329525 | 0.80 | PTGS2 (0.55) | PTGS2NQO1CA12CA1CA9 | |
| SCHEMBL1627582 | 0.78 | CYP2A6 (0.64) | PTGS2NQO1CA12CA1CA9 | |
| SCHEMBL14802542 | 0.77 | CA12 (0.61) | PTGS2NQO1CA12CA1CA9 | |
| SCHEMBL24523050 | 0.76 | ALDH1A1 (0.59) | PTGS2NQO1CA12CA1CA9 | |
| SCHEMBL15842820 | 0.76 | CA12 (0.55) | PTGS2NQO1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130079394-A1 | Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods | CNRS (CENTRE NATIONAL RECHERCHE SCIENTIFIQUE) (FR) | 2013-03-28 | — | — | US | disclosed |
| US-20130079394-A1 | Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods | CNRS (CENTRE NATIONAL RECHERCHE SCIENTIFIQUE) (FR) | 2013-03-28 | — | — | US | disclosed |
| WO-2013003168-A1 | NOVEL INSECT-REPELLENT COUMARIN DERIVATIVES, SYNTHESES, AND METHODS OF USE | MERIAL LIMITED (US) | 2013-01-03 | — | — | WO | disclosed |
| US-20120329832-A1 | Novel Insect-Repellent Coumarin Derivatives, Syntheses, and Methods of Use | MERIAL LIMITED | 2012-12-27 | — | — | US | disclosed |
| US-20120329832-A1 | Novel Insect-Repellent Coumarin Derivatives, Syntheses, and Methods of Use | MERIAL LIMITED | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079394-A1 | Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods | NISCH, ACAT2, CIAPIN1 | PTGS2 4622/4885NQO1 1598/4885CA12 3214/4885 |
| US-20120329832-A1 | Novel Insect-Repellent Coumarin Derivatives, Syntheses, and Methods of Use | NISCH, PCSK6, CYP51A1 | PTGS2 3481/4885NQO1 844/4885CA12 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.